<DOC>
	<DOCNO>NCT00856856</DOCNO>
	<brief_summary>The purpose study assess safety performance BVS Everolimus Eluting Coronary Stent System ( EECSS ) treatment patient maximum two de novo native coronary artery lesion locate two different major epicardial vessel . Currently development Abbott Vascular . Not available sale United States .</brief_summary>
	<brief_title>ABSORB Clinical Investigation , Cohort B</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Restenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>General inclusion criterion 1 . Patient must least 18 year age . 2 . Patient able verbally confirm understand risk , benefit treatment alternative receive BVS Everolimus Eluting CSS he/she his/her legally authorize representative provide write informed consent prior Clinical Investigation related procedure , approve appropriate Ethics Committee respective clinical site . 3 . Patient must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia , positive functional study reversible change electrocardiogram ( ECG ) consistent ischemia ) 4 . Patient must acceptable candidate coronary artery bypass graft ( CABG ) surgery 5 . Patient must agree undergo clinical investigation planrequired followup visit , angiogram , intravascular ultrasound ( IVUS ) , Palpography ( optional ) , optical coherence tomography ( OCT ) ( strongly recommend ) , multislice compute tomography ( MSCT ) ( optional ) coronary vasomotion ( optional ) 6 . Patient must agree participate clinical investigation period two year follow index procedure Angiographic Inclusion Criteria 1 . Target lesion ( ) must locate native coronary artery visually estimate nominal vessel diameter 3.0 mm 2 . Target lesion ( ) must measure ≤ 14 mm length visual estimation 3 . Target lesion ( ) must major artery branch visually estimate stenosis ≥ 50 % &lt; 100 % TIMI flow ≥ 1 4 . If two target lesion meet inclusion criterion must different major epicardial vessel leave anterior descend artery ( LAD ) septal diagonal branch , leave circumflex artery ( LCX ) obtuse marginal and/or ramus intermedius branch right coronary artery ( RCA ) branch 5 . If two target lesion ( ) treat , lesion must meet angiographic inclusion/exclusion criterion 6 . NonClinical Investigation , percutaneous intervention lesion nontarget vessel allow do ≥ 90 day prior plan do 6 month index procedure 7 . NonClinical Investigation percutaneous intervention lesion target vessel allow do &gt; 6 month prior plan do 6 month index procedure General Exclusion Criteria 1 . Patients know diagnosis acute myocardial infarction ( AMI ) within 3 day precede index procedure creatine kinase ( CK ) CKMB ( creatine kinasemyoglobin ) return within normal limit time procedure 2 . The patient currently experience clinical symptom consistent AMI 3 . Patient current unstable arrhythmia 4 . Patient know leave ventricular ejection fraction ( LVEF ) &lt; 30 % 5 . Patient receive heart transplant organ transplant wait list organ transplant 6 . Patient receive schedule receive chemotherapy malignancy within 30 day prior procedure 7 . Patient receive immunosuppression therapy know immunosuppressive autoimmune disease ( e.g . human immunodeficiency virus , systemic lupus erythematosus etc . ) 8 . Patient receive schedule receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) 9 . Patient known hypersensitivity contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , everolimus , poly ( Llactide ) , poly ( DLlactide ) contrast sensitivity adequately premedicated 10 . Elective surgery plan within first 6 month procedure require discontinue either aspirin clopidogrel 11 . Patient platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , white blood cell count &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) 12 . Patient known renal insufficiency ( e.g. , serum creatinine level 2.5 mg/dL , patient dialysis ) 13 . Patient history bleed diathesis coagulopathy refuse blood transfusion 14 . Patient cerebrovascular accident ( CVA ) transient ischemic neurological attack ( TIA ) within past six month 15 . Patient significant GI urinary bleed within past six month 16 . Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion 17 . Patient medical illness ( e.g. , cancer congestive heart failure ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance clinical investigation plan , confound data interpretation associate limited life expectancy ( i.e. , less one year ) 18 . Patient already participate another clinical investigation yet reach primary endpoint 19 . Pregnant nursing patient plan pregnancy Clinical Investigation . ( Female patient childbearing potential must negative pregnancy test do within 7 day prior index procedure effective contraception must use participation Clinical Investigation ) 20 . Patient receive brachytherapy epicardial vessel ( include side branch ) Angiographic Exclusion Criteria 1 . Target lesion ( ) meet follow criterion : 1 . Aortoostial location ( within 3 mm ) 2 . Left main location 3 . Located within 2 mm origin LAD LCX 4 . Located within arterial saphenous vein graft distal diseased ( defined vessel irregularity per angiogram &gt; 20 % stenosed lesion , visual estimation ) arterial saphenous vein graft 5 . Lesion involve bifurcation ≥ 2 mm diameter ostial lesion &gt; 40 % stenosed visual estimation side branch require predilatation 6 . Total occlusion ( TIMI flow 0 ) , prior wire cross 7 . Excessive tortuosity proximal within lesion 8 . Extreme angulation ( ≥ 90 % ) proximal within lesion 9 . Heavy calcification 10 . Restenotic previous intervention 2 . The target vessel contain visible thrombus 3 . Another clinically significant lesion locate major epicardial vessel target lesion ( ) ( include side branch ) 4 . Patient high probability procedure predilatation stenting ( necessary ) postdilatation require time index procedure treatment target vessel ( e.g . atherectomy , cut balloon brachytherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bioabsorbable</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>drug elute stent</keyword>
	<keyword>stent</keyword>
	<keyword>angioplasty</keyword>
	<keyword>coronary artery disease</keyword>
	<keyword>total coronary occlusion</keyword>
	<keyword>coronary artery restenosis</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>vascular disease</keyword>
	<keyword>myocardial ischemia</keyword>
	<keyword>coronary artery stenosis</keyword>
	<keyword>CAD</keyword>
	<keyword>CAOD</keyword>
</DOC>